Diabetes and microalbuminuria in heart transplant recipients – insights from baseline characteristics of the Empagliflozin in Heart Transplant (EMPA-HTx) trial (TTS 2026) - Sep 17, 2026 - Abstract #P2.245; Pres time: Sep 22, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P2; P2/3 | "In an interim analysis of baseline data from an ongoing trial, there were no differences in non-glycaemic baseline characteristics between those with and without pre-existing diabetes. When completed, this study will provide data on the efficacy and safety of SGLT2i in HTx recipients."
Clinical • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Transplantation
|
|
Lisa Raven1,2,3; Christopher Muir1,2; Peter Macdonald3,4,5; Andrew Jabbour3,4,5; Jerry Greenfield1,2,3,4
|